All Outputs (2)

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies (2013)
Journal Article
Khan, G., Denniss, F., Mills, K. I., Guinn, B.-A., & Pulford, K. (2013). PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies. Genetic Syndromes and Gene Therapy, 04(09), Article 186. https://doi.org/10.4172/2157-7412.1000186

In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in... Read More about PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies.

An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide (2013)
Journal Article
Hardwick, N., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G., Stevenson, F., & Guinn, B. A. (2013). An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. Cancer Immunology Research, 13(3), 16-26. https://doi.org/10.1158/1424-9634.DCL-16.13.3

We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the ca... Read More about An analogue peptide from the cancer/testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.